Formycon AG (FSB: FYB, Prime Standard) announced it will publish its financial results for the fiscal year 2025 on April 22, 2026. The Management Board will discuss the company's development, key financial figures, and provide an outlook for the 2026 fiscal year during a conference call broadcast live on the internet at 3:00 PM CEST on the same day. To participate, registration is available at this link. After registration, participants will receive a confirmation email with individual dial-in data.
The presentation and audio broadcast can be accessed via this webcast link. Following a brief presentation, the Management Board will be available for analysts' questions. The conference call will be recorded and subsequently accessible via the Formycon website at this page.
Representatives of the Management Board will attend several events and investor conferences in the second quarter of 2026. On May 11-12, 2026, CFO Enno Spillner will attend the Equity Forum Spring Conference in Frankfurt, Germany. On May 28, 2026, the company will publish results for the first quarter of 2026, followed by a conference call with CEO Dr. Stefan Glombitza, CFO Enno Spillner, CBO Nicola Mikulcik, and CSO Dr. Andreas Seidl. On June 2-4, 2026, CFO Enno Spillner will attend the Jefferies Global Healthcare Conference in New York City. On June 8, 2026, the management team will participate in the mwb research Roundtable via webcast. The Annual General Meeting will take place on June 10, 2026, at Haus der Bayerischen Wirtschaft in Munich. On June 18, 2026, CFO Enno Spillner will attend the UBS Life Sciences Conference in London, UK. A full financial calendar is available at Formycon's investor relations page.
Formycon is a leading independent developer of high-quality biosimilars, focusing on therapies in ophthalmology, immunology, immuno-oncology, and other key disease areas. The company covers almost the entire value chain from technical development through clinical trials to regulatory approval. With FYB201/ranibizumab and FYB202/ustekinumab, Formycon already has two biosimilars on the market, and FYB203/aflibercept has been approved by the FDA, EMA, and MHRA. Four pipeline candidates, including FYB208/dupilumab, are currently in development. The company's biosimilars aim to provide broader patient access to effective and affordable medicines.
